Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial

Dongmei Ji, Shufang Wang, Wei Yao, Dibo Hou, Xiaoyan Wang, Changsheng Ye, Hongsheng Li, Hongjian Yang, Yi Jilin, Jingjing Lu, Haibo Wang, X Xu, Dongyan Cai, Xiaoan Liu, Xi Yan, Jianyun Nie, Shude Cui, Hongchuan Jiang, Junning CaoClinical 2025 · DOI

Abstract

ClinicalTrials.gov: NCT02521441. This Phase II trial evaluates efbemalenograstim alfa, a non-PEGylated Fc-fusion protein, as a long-acting alternative to daily filgrastim for preventing chemotherapy-induced neutropenia (CIN).

Introduction

Myelosuppressive chemotherapy frequently causes neutropenia, a significant reduction in absolute neutrophil counts (ANC) that increases infection risk. While Granulocyte Colony-Stimulating Factors (G-CSFs) like filgrastim are standard treatments, short-acting versions require daily injections for up to two weeks. Existing long-acting versions typically use PEGylation (adding polyethylene glycol) to extend half-life, which can trigger anti-PEG antibody responses that reduce efficacy or cause allergic reactions. Efbemalenograstim alfa (F-627) addresses this by using an Fc-fusion design to extend half-life without PEGylation.

Methods

This multicenter, randomized, open-label Phase II trial enrolled 138 female breast cancer patients receiving epirubicin and cyclophosphamide (EC) chemotherapy. Patients were randomized into three groups: efbemalenograstim alfa at 10 mg or 20 mg (single injection per cycle), or daily filgrastim (5 μg/kg/day).

Study flow diagram showing screening, randomization, and analysis sets.

The study drug is a G-CSF-Fc fusion protein that utilizes the natural neonatal Fc receptor (FcRn) recycling pathway to achieve a half-life of approximately three weeks, aligning with standard chemotherapy cycles. Analysis was performed on Intent-to-Treat (ITT), Per-Protocol (PP), and Safety sets.

Results

Both doses of efbemalenograstim alfa demonstrated non-inferiority to filgrastim. In Cycle 1, the 20 mg dose group had a mean duration of moderate/severe neutropenia of 0.6 days, compared to 0.8 days for the filgrastim group.

Median absolute neutrophil count (ANC) over 21 days of treatment for the three study groups.

As shown in Figure 3, the 20 mg dose group maintained a higher median ANC nadir ($2.2 \times 10^9/L$) than the filgrastim group ($1.4 \times 10^9/L$), suggesting superior protection during the cycle's lowest point. Furthermore, the 20 mg group exhibited faster ANC recovery post-nadir (0.8 days vs. 1.2 days). Safety profiles were favorable, with lower drug-related adverse events in the 20 mg group (10.0%) compared to filgrastim (31.7%), and no development of neutralizing antibodies.

Discussion and Conclusion

Efbemalenograstim alfa offers a promising "non-PEG" advantage, potentially avoiding issues related to anti-PEG antibodies while providing the convenience of a single injection. The dimeric structure of the fusion protein may also enhance G-CSF receptor activation compared to monomeric forms. While this Phase II study is limited by its sample size and focus on a specific cancer type, the results support the 20 mg dose for further Phase III investigation. This novel Fc-fusion protein represents a significant step toward more effective and patient-friendly management of chemotherapy-induced neutropenia.

Summary updated

Abstract

ClinicalTrials.gov: NCT02521441, on 13 August 2015.
BibTeX
@inproceedings{ji2025efbemalenograstim,
  author = {Dongmei Ji and Shufang Wang and Wei Yao and Dibo Hou and Xiaoyan Wang and Changsheng Ye and Hongsheng Li and Hongjian Yang and YI Jilin and Jingjing Lu and Haibo Wang and X XU and Dongyan Cai and Xiaoan Liu and Xi Yan and Jianyun Nie and Shude Cui and Hongchuan Jiang and Junning Cao},
  title = {{Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1007/s40261-025-01479-y},
}
Figure